ruxolitinib

Better late than never? Eczema drug now approved, Incyte says warning unwarranted

Atopic dermatitis patients now have a new therapeutic option that comes as a topical cream. The FDA approved Incyte’s drug, Opzelura, as a treatment for the inflammatory skin condition, but the regulatory nod comes with a black box warning on the label that broadly covers the entire class of JAK inhibitors.

By Frank Vinluan

BioPharma

Incyte plans Phase III trial of blood cancer drug as potential Covid-19 cytokine storm therapy

The company said it is working with the FDA to start a Phase III study of Jakafi in Covid-19-associated cytokine storm, which may be behind severe disease in some patients and for which JAK inhibitors have been suggested as a possible therapeutic option.

By Alaric DeArment

Healthcare

Using Data to Help Healthcare Practices Succeed

A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.

By Relatient